The Ohio State University Wexner Medical Center
Obstetrics and Gynecology residency · Columbus, OH · Program website
This program's roster hasn't been collected yet, so there's no list of its own faculty and papers. Below is The Ohio State University Wexner Medical Center's research in obstetrics and gynecology, which the program shares with other departments and affiliated hospitals.
About The Ohio State University Wexner Medical Centerinstitution-wide obstetrics and gynecology research
Obstetrics and Gynecology publications from The Ohio State University Wexner Medical Center and affiliated institutions, since 2022. Updated 2026-11-06; refreshed daily.
63
works per year
23rd of 81 obstetrics and gynecology residency programs
-11.3%
2-year growth
59th of 80 obstetrics and gynecology residency programs
27.9%
in top 10% of field (works before 2025)
19th of 67 obstetrics and gynecology residency programs
53.6%
cited above world average
12th of 67 obstetrics and gynecology residency programs
Works per year · * 2026 so far
Obstetrics and Gynecology · 203Reproductive Medicine · 115
Obstetrics and Gynecology research topics at The Ohio State University Wexner Medical Center
Papers in the window; each links to the list on OpenAlex.
- Endometrial and Cervical Cancer Treatments 119
- Ovarian cancer diagnosis and treatment 106
- Pregnancy and preeclampsia studies 31
- Gestational Diabetes Research and Management 24
- Maternal and Perinatal Health Interventions 12
- Uterine Myomas and Treatments 11
- Endometriosis Research and Treatment 5
- Sperm and Testicular Function 4
Most cited at The Ohio State University Wexner Medical Center since 2024
All obstetrics and gynecology papers there on OpenAlex
- ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancerToon Van Gorp et al. · Annals of Oncology · 2024 · PubMed · cited 103
- Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trialRamez Nassef Eskander et al. · Nature Medicine · 2025 · PubMed · cited 93
- NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025Nadeem R. Abu‐Rustum et al. · Journal of the National Comprehensive Cancer Network · 2025 · PubMed · cited 82
- Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In OncologyNadeem R. Abu‐Rustum et al. · Journal of the National Comprehensive Cancer Network · 2025 · PubMed · cited 46
- Patient-reported outcomes from the MIRASOL trial evaluating mirvetuximab soravtansine versus chemotherapy in patients with folate receptor α-positive, platinum-resistant ovarian cancer: a randomised, open-label, phase 3 trialToon Van Gorp et al. · The Lancet Oncology · 2025 · PubMed · cited 45
- Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical TrialAnn H. Klopp et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 30
- Pembrolizumab or Placebo Plus Adjuvant Chemotherapy With or Without Radiotherapy for Newly Diagnosed, High-Risk Endometrial Cancer: Results in Mismatch Repair-Deficient TumorsBrian M. Slomovitz et al. · Journal of Clinical Oncology · 2024 · PubMed · cited 28
- Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trialJyoti Mayadev et al. · Nature Communications · 2025 · PubMed · cited 27
- Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study resultsDavid M. O’Malley et al. · Gynecologic Oncology · 2025 · PubMed · cited 26
- Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)Matthew A. Powell et al. · Gynecologic Oncology · 2024 · PubMed · cited 26